About this Journal Submit a Manuscript Table of Contents
Scientifica
Volume 2013 (2013), Article ID 125705, 29 pages
http://dx.doi.org/10.1155/2013/125705
Review Article

The Role of Inflammatory Cytokines, the RANKL/OPG Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and Osteoporosis

1Atlanta Department of Veterans Affairs Medical Center, Decatur, GA 30033, USA
2Division of Endocrinology and Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, 101 Woodruff Circle, 1305 WMRB, Atlanta, GA 30322, USA

Received 6 December 2012; Accepted 24 December 2012

Academic Editors: G. Da Silva Xavier and E. Hajduch

Copyright © 2013 M. Neale Weitzmann. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Weiner and W. Traub, “Bone structure: from angstroms to microns,” The FASEB Journal, vol. 6, no. 3, pp. 879–885, 1992. View at Scopus
  2. T. A. Franz-Odendaal, “Induction and patterning of intramembranous bone,” Frontiers in Bioscience, vol. 16, no. 7, pp. 2734–2746, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. S. C. Manolagas, “Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis,” Endocrine Reviews, vol. 21, no. 2, pp. 115–137, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. S. C. Manolagas and R. L. Jilka, “Mechanisms of disease: bone marrow, cytokines, and bone remodeling—emerging insights into the pathophysiology of osteoporosis,” The New England Journal of Medicine, vol. 332, no. 5, pp. 305–311, 1995. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Khosla, S. Amin, and E. Orwoll, “Osteoporosis in men,” Endocrine Reviews, vol. 29, no. 4, pp. 441–464, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. J. A. Eisman, E. R. Bogoch, R. Dell et al., “Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention,” Journal of Bone and Mineral Research, vol. 27, no. 10, pp. 2039–2046, 2012. View at Publisher · View at Google Scholar
  7. O. Johnell and J. A. Kanis, “An estimate of the worldwide prevalence and disability associated with osteoporotic fractures,” Osteoporosis International, vol. 17, no. 12, pp. 1726–1733, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. C. J. Todd, C. J. Freeman, C. Camilleri-Ferrante et al., “Differences in mortality after fracture of hip: the East Anglian audit,” British Medical Journal, vol. 310, no. 6984, pp. 904–908, 1995. View at Scopus
  9. D. M. Black, L. Palermo, M. C. Nevitt et al., “Comparison of methods for defining prevalent vertebral deformities: the study of osteoporotic fractures,” Journal of Bone and Mineral Research, vol. 10, no. 6, pp. 890–902, 1995. View at Scopus
  10. “Prevention and management of osteoporosis,” World Health Organization Technical Report Series, vol. 921, pp. 1–164, 2003.
  11. J. R. Lewis, S. K. Z. Hassan, R. T. Wenn, and C. G. Moran, “Mortality and serum urea and electrolytes on admission for hip fracture patients,” Injury, vol. 37, no. 8, pp. 698–704, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Brainsky, H. Glick, E. Lydick et al., “The economic cost of hip fractures in community-dwelling older adults: a prospective study,” Journal of the American Geriatrics Society, vol. 45, no. 3, pp. 281–287, 1997. View at Scopus
  13. R. Burge, B. Dawson-Hughes, D. H. Solomon, J. B. Wong, A. King, and A. Tosteson, “Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025,” Journal of Bone and Mineral Research, vol. 22, no. 3, pp. 465–475, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. M. C. Horowitz and J. A. Lorenzo, “The origins of osteoclasts,” Current Opinion in Rheumatology, vol. 16, no. 4, pp. 464–468, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. M. N. Weitzmann and R. Pacifici, “The role of T lymphocytes in bone metabolism,” Immunological Reviews, vol. 208, pp. 154–168, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Takayanagi, “Mechanistic insight into osteoclast differentiation in osteoimmunology,” Journal of Molecular Medicine, vol. 83, no. 3, pp. 170–179, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. M. N. Weitzmann and R. Pacifici, “Estrogen deficiency and bone loss: an inflammatory tale,” Journal of Clinical Investigation, vol. 116, no. 5, pp. 1186–1194, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Lorenzo, M. Horowitz, and Y. Choi, “Osteoimmunology: interactions of the bone and immune system,” Endocrine Reviews, vol. 29, no. 4, pp. 403–440, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. I. Ofotokun and M. N. Weitzmann, “HIV-1 infection and antiretroviral therapies: risk factors for osteoporosis and bone fracture,” Current Opinion in Endocrinology, Diabetes and Obesity, vol. 17, no. 6, pp. 523–529, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Leibbrandt and J. M. Penninger, “Novel functions of RANK(L) signaling in the immune system,” Advances in Experimental Medicine and Biology, vol. 658, pp. 77–94, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. I. Ofotokun and M. N. Weitzmann, “HIV and bone metabolism,” Discovery Medicine, vol. 11, pp. 385–393, 2011.
  22. I. Ofotokun, E. McIntosh, and M. N. Weitzmann, “HIV: inflammation and bone,” Current HIV/AIDS Reports, vol. 9, pp. 16–25, 2012.
  23. R. Pacifici, “Role of T cells in ovariectomy induced bone loss—revisited,” Journal of Bone and Mineral Research, vol. 27, pp. 231–239, 2012.
  24. R. Baron, L. Neff, W. Brown, D. Louvard, and P. J. Courtoy, “Selective internalization of the apical plasma membrane and rapid redistribution of lysosomal enzymes and mannose 6-phosphate receptors during osteoclast inactivation by calcitonin,” Journal of Cell Science, vol. 97, no. 3, pp. 439–447, 1990. View at Scopus
  25. S. L. Teitelbaum, “Bone resorption by osteoclasts,” Science, vol. 289, no. 5484, pp. 1504–1508, 2000. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Pacifici, C. Brown, E. Puscheck et al., “Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 12, pp. 5134–5138, 1991. View at Publisher · View at Google Scholar · View at Scopus
  27. S. C. Manolagas, T. Bellido, and R. L. Jilka, “New insights into the cellular, biochemical, and molecular basis of postmenopausal and senile osteoporosis: roles of IL-6 and gp130,” International Journal of Immunopharmacology, vol. 17, no. 2, pp. 109–116, 1995. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Takahashi, T. Akatsu, N. Udagawa et al., “Osteoblastic cells are involved in osteoclast formation,” Endocrinology, vol. 123, no. 5, pp. 2600–2602, 1988. View at Scopus
  29. W. S. Simonet, D. L. Lacey, C. R. Dunstan et al., “Osteoprotegerin: a novel secreted protein involved in the regulation of bone density,” Cell, vol. 89, no. 2, pp. 309–319, 1997. View at Scopus
  30. E. Tsuda, M. Goto, S. I. Mochizuki et al., “Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis,” Biochemical and Biophysical Research Communications, vol. 234, no. 1, pp. 137–142, 1997. View at Publisher · View at Google Scholar · View at Scopus
  31. D. L. Lacey, E. Timms, H. L. Tan et al., “Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation,” Cell, vol. 93, no. 2, pp. 165–176, 1998. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Matsuzaki, N. Udagawa, N. Takahashi et al., “Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures,” Biochemical and Biophysical Research Communications, vol. 246, no. 1, pp. 199–204, 1998. View at Publisher · View at Google Scholar · View at Scopus
  33. D. M. Anderson, E. Maraskovsky, W. L. Billingsley et al., “A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function,” Nature, vol. 390, no. 6656, pp. 175–179, 1997. View at Publisher · View at Google Scholar · View at Scopus
  34. B. R. Wong, R. Josien, S. Y. Lee et al., “TRANCE (Tumor necrosis factor [TNF]-related Activation-induced Cytokine), a new TNF family member predominantly expressed in t cells, is a dendritic cell-specific survival factor,” The Journal of Experimental Medicine, vol. 186, no. 12, pp. 2075–2080, 1997. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Hsu, D. L. Lacey, C. R. Dunstan et al., “Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 7, pp. 3540–3545, 1999. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Khosla, “Minireview: the OPG/RANKL/RANK system,” Endocrinology, vol. 142, no. 12, pp. 5050–5055, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. T. Suda, N. Takahashi, N. Udagawa, E. Jimi, M. T. Gillespie, and T. J. Martin, “Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families,” Endocrine Reviews, vol. 20, no. 3, pp. 345–357, 1999. View at Scopus
  38. H. J. Choi, Y. R. Park, M. Nepal et al., “Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF-κB signaling pathways,” European Journal of Pharmacology, vol. 636, no. 1–3, pp. 28–35, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Maruyama, H. Fukushima, K. Nakao et al., “Processing of the NF-κB2 precursor p100 to p52 is critical for RANKL-induced osteoclast differentiation,” Journal of Bone and Mineral Research, vol. 25, no. 5, pp. 1058–1067, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Ogasawara, M. Katagiri, A. Yamamoto et al., “Osteoclast differentiation by RANKL requires NF-κB-mediated downregulation of cyclin-dependent kinase 6 (Cdk6),” Journal of Bone and Mineral Research, vol. 19, no. 7, pp. 1128–1136, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Vaira, M. Alhawagri, I. Anwisye, H. Kitaura, R. Faccio, and D. V. Novack, “RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice,” Journal of Clinical Investigation, vol. 118, no. 6, pp. 2088–2097, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Srivastava, M. N. Weitzmann, S. Cenci, F. P. Ross, S. Adler, and R. Pacifici, “Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD,” Journal of Clinical Investigation, vol. 104, no. 4, pp. 503–513, 1999. View at Scopus
  43. S. Srivastava, G. Toraldo, M. N. Weitzmann, S. Cenci, F. P. Ross, and R. Pacifici, “Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-κB ligand (RANKL)-induced JNK activation,” Journal of Biological Chemistry, vol. 276, no. 12, pp. 8836–8840, 2001. View at Publisher · View at Google Scholar · View at Scopus
  44. H. Hirotani, N. A. Tuohy, J. T. Woo, P. H. Stern, and N. A. Clipstone, “The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells,” Journal of Biological Chemistry, vol. 279, no. 14, pp. 13984–13992, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. K. Matsuo, D. L. Galson, C. Zhao et al., “Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos,” Journal of Biological Chemistry, vol. 279, no. 25, pp. 26475–26480, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. H. Takayanagi, “The role of NFAT in osteoclast formation,” Annals of the New York Academy of Sciences, vol. 1116, pp. 227–237, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. M. H. Helfrich, C. W. Thesingh, R. H. P. Mieremet, and A. S. van Iperen-van Gent, “Osteoclast generation from human fetal bone marrow in cocultures with murine fetal long bones. A model for in vitro study of human osteoclast formation and function,” Cell and Tissue Research, vol. 249, no. 1, pp. 125–136, 1987. View at Scopus
  48. T. Inaoka, G. Bilbe, O. Ishibashi, K. I. Tezuka, M. Kumegawa, and T. Kokubo, “Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone,” Biochemical and Biophysical Research Communications, vol. 206, no. 1, pp. 89–96, 1995. View at Publisher · View at Google Scholar · View at Scopus
  49. B. F. Boyce, T. Yoneda, C. Lowe, P. Soriano, and G. R. Mundy, “Requirement of pp60(c-src) expression for osteoclasts to form ruffled borders and resorb bone in mice,” Journal of Clinical Investigation, vol. 90, no. 4, pp. 1622–1627, 1992. View at Scopus
  50. T. A. Hentunen, S. H. Jackson, H. Chung et al., “Characterization of immortalized osteoclast precursors developed from mice transgenic for both bcl-X(L) and simian virus 40 large T antigen,” Endocrinology, vol. 140, no. 7, pp. 2954–2961, 1999. View at Scopus
  51. J. Clover, R. A. Dodds, and M. Gowen, “Integrin subunit expression by human osteoblasts and osteoclasts in situ and in culture,” Journal of Cell Science, vol. 103, no. 1, pp. 267–271, 1992. View at Scopus
  52. S. L. Teitelbaum, “The osteoclast and its unique cytoskeleton,” Annals of the New York Academy of Sciences, vol. 1240, pp. 14–17, 2011.
  53. M. J. Oursler, L. V. Bell, B. Clevinger, and P. Osdoby, “Identification of osteoclast-specific monoclonal antibodies,” Journal of Cell Biology, vol. 100, no. 5, pp. 1592–1600, 1985. View at Scopus
  54. Y. Y. Kong, H. Yoshida, I. Sarosi et al., “OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis,” Nature, vol. 397, no. 6717, pp. 315–323, 1999. View at Publisher · View at Google Scholar · View at Scopus
  55. N. Bucay, I. Sarosi, C. R. Dunstan et al., “Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification,” Genes and Development, vol. 12, no. 9, pp. 1260–1268, 1998. View at Scopus
  56. H. Min, S. Morony, I. Sarosi et al., “Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis,” The Journal of Experimental Medicine, vol. 192, no. 4, pp. 463–474, 2000. View at Publisher · View at Google Scholar · View at Scopus
  57. A. E. Hughes, S. H. Ralston, J. Marken et al., “Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis,” Nature Genetics, vol. 24, no. 1, pp. 45–48, 2000. View at Publisher · View at Google Scholar · View at Scopus
  58. M. P. Whyte, S. E. Obrecht, P. M. Finnegan et al., “Osteoprotegerin deficiency and juvenile Paget's disease,” The New England Journal of Medicine, vol. 347, no. 3, pp. 175–184, 2002. View at Publisher · View at Google Scholar · View at Scopus
  59. M. P. Whyte, P. N. Singhellakis, M. B. Petersen, M. Davies, W. G. Totty, and S. Mumm, “Juvenile Paget's disease: the second reported, oldest patient is homozygous for the TNFRSF11B “Balkan” mutation (966_969delTGACinsCTT), which elevates circulating immunoreactive osteoprotegerin levels,” Journal of Bone and Mineral Research, vol. 22, no. 6, pp. 938–946, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. M. P. Whyte and S. Mumm, “Heritable disorders of the RANKL/OPG/RANK signaling pathway,” Journal of Musculoskeletal Neuronal Interactions, vol. 4, no. 3, pp. 254–267, 2004. View at Scopus
  61. M. P. Whyte, W. G. Totty, D. V. Novack, X. Zhang, D. Wenkert, and S. Mumm, “Camurati-engelmann disease: unique variant featuring a novel mutation in TGFβ1 encoding transforming growth factor beta 1 and a missense change in TNFSF11 encoding RANK ligand,” Journal of Bone and Mineral Research, vol. 26, no. 5, pp. 920–933, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. B. Bolon, C. Carter, M. Daris et al., “Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis,” Molecular Therapy, vol. 3, no. 2, pp. 197–205, 2001. View at Publisher · View at Google Scholar · View at Scopus
  63. C. Capparelli, S. Morony, K. Warmington et al., “Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats,” Journal of Bone and Mineral Research, vol. 18, no. 5, pp. 852–858, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. M. S. Ominsky, P. J. Kostenuik, P. Cranmer, S. Y. Smith, and J. E. Atkinson, “The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys,” Osteoporosis International, vol. 18, no. 8, pp. 1073–1082, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. P. J. Bekker, D. Holloway, A. Nakanishi, M. Arrighi, P. T. Leese, and C. R. Dunstan, “The effect of a single dose of osteoprotegerin in postmenopausal women,” Journal of Bone and Mineral Research, vol. 16, no. 2, pp. 348–360, 2001. View at Scopus
  66. M. R. McClung, E. M. Lewiecki, S. B. Cohen et al., “Denosumab in postmenopausal women with low bone mineral density,” The New England Journal of Medicine, vol. 354, no. 8, pp. 821–831, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. S. R. Cummings, J. S. Martin, M. R. McClung et al., “Denosumab for prevention of fractures in postmenopausal women with osteoporosis,” The New England Journal of Medicine, vol. 361, no. 8, pp. 756–765, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. L. C. Hofbauer, D. L. Lacey, C. R. Dunstan, T. C. Spelsberg, B. L. Riggs, and S. Khosla, “Interleukin-1β and tumor necrosis factor-κ, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells,” Bone, vol. 25, no. 3, pp. 255–259, 1999. View at Publisher · View at Google Scholar · View at Scopus
  69. S. Wei, H. Kitaura, P. Zhou, F. Patrick Ross, and S. L. Teitelbaum, “IL-1 mediates TNF-induced osteoclastogenesis,” Journal of Clinical Investigation, vol. 115, no. 2, pp. 282–290, 2005. View at Publisher · View at Google Scholar · View at Scopus
  70. M. N. Weitzmann, C. Roggia, G. Toraldo, L. Weitzmann, and R. Pacifici, “Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency,” Journal of Clinical Investigation, vol. 110, no. 11, pp. 1643–1650, 2002. View at Publisher · View at Google Scholar · View at Scopus
  71. F. Arai, T. Miyamoto, O. Ohneda et al., “Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor κB (RANK) receptors,” The Journal of Experimental Medicine, vol. 190, no. 12, pp. 1741–1754, 1999. View at Publisher · View at Google Scholar · View at Scopus
  72. R. Pacifici, J. L. Vannice, L. Rifas, and R. B. Kimble, “Monocytic secretion of interleukin-1 receptor antagonist in normal and osteoporotic women: effects of menopause and estrogen/progesterone therapy,” Journal of Clinical Endocrinology and Metabolism, vol. 77, no. 5, pp. 1135–1141, 1993. View at Publisher · View at Google Scholar · View at Scopus
  73. R. B. Kimble, J. L. Vannice, D. C. Bloedow et al., “Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats,” Journal of Clinical Investigation, vol. 93, no. 5, pp. 1959–1967, 1994. View at Scopus
  74. R. Kitazawa, R. B. Kimble, J. L. Vannice, V. T. Kung, and R. Pacifici, “Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice,” Journal of Clinical Investigation, vol. 94, no. 6, pp. 2397–2406, 1994. View at Scopus
  75. R. B. Kimble, A. B. Matayoshi, J. L. Vannice, V. T. Kung, C. Williams, and R. Pacifici, “Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period,” Endocrinology, vol. 136, no. 7, pp. 3054–3061, 1995. View at Scopus
  76. R. B. Kimble, S. Srivastava, F. Patrick Ross, A. Matayoshi, and R. Pacifici, “Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1-and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production,” Journal of Biological Chemistry, vol. 271, no. 46, pp. 28890–28897, 1996. View at Publisher · View at Google Scholar · View at Scopus
  77. S. Cenci, M. N. Weitzmann, C. Roggia et al., “Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-α,” Journal of Clinical Investigation, vol. 106, no. 10, pp. 1229–1237, 2000. View at Scopus
  78. J. Lam, S. Takeshita, J. E. Barker, O. Kanagawa, F. P. Ross, and S. L. Teitelbaum, “TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand,” Journal of Clinical Investigation, vol. 106, no. 12, pp. 1481–1488, 2000. View at Scopus
  79. K. Fuller, C. Murphy, B. Kirstein, S. W. Fox, and T. J. Chambers, “TNFα potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL,” Endocrinology, vol. 143, no. 3, pp. 1108–1118, 2002. View at Publisher · View at Google Scholar · View at Scopus
  80. Y. H. Zhang, A. Heulsmann, M. M. Tondravi, A. Mukherjee, and Y. Abu-Amer, “Tumor necrosis factor-α (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways,” Journal of Biological Chemistry, vol. 276, no. 1, pp. 563–568, 2001. View at Publisher · View at Google Scholar · View at Scopus
  81. K. Kobayashi, N. Takahashi, E. Jimi et al., “Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction,” The Journal of Experimental Medicine, vol. 191, no. 2, pp. 275–285, 2000. View at Publisher · View at Google Scholar · View at Scopus
  82. K. Redlich, B. Görtz, S. Hayer et al., “Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis,” American Journal of Pathology, vol. 164, no. 2, pp. 543–555, 2004. View at Scopus
  83. N. Saidenberg-Kermanac'H, A. Corrado, D. Lemeiter, M. C. deVernejoul, M. C. Boissier, and M. E. Cohen-Solal, “TNF-α antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis,” Bone, vol. 35, no. 5, pp. 1200–1207, 2004. View at Publisher · View at Google Scholar · View at Scopus
  84. A. M. Reimold, “New indications for treatment of chronic inflammation by TNF-α blockade,” American Journal of the Medical Sciences, vol. 325, no. 2, pp. 75–92, 2003. View at Publisher · View at Google Scholar · View at Scopus
  85. B. F. Boyce, L. Xing, G. Franzoso, and U. Siebenlist, “Required and nonessential functions of nuclear factor-kappa B in bone cells,” Bone, vol. 25, no. 1, pp. 137–139, 1999. View at Publisher · View at Google Scholar · View at Scopus
  86. T. J. Hall, M. Schaeublin, H. Jeker, K. Fuller, and T. J. Chambers, “The role of reactive oxygen intermediates in osteoclastic bone resorption,” Biochemical and Biophysical Research Communications, vol. 207, no. 1, pp. 280–287, 1995. View at Publisher · View at Google Scholar · View at Scopus
  87. S. Vaira, T. Johnson, A. C. Hirbe et al., “RelB is the NF-κB subunit downstream of NIK responsible for osteoclast differentiation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 10, pp. 3897–3902, 2008. View at Publisher · View at Google Scholar · View at Scopus
  88. J. Liu, S. Wang, P. Zhang, N. Said-Al-Naief, S. M. Michalek, and X. Feng, “Molecular mechanism of the bifunctional role of lipopolysaccharide in osteoclastogenesis,” Journal of Biological Chemistry, vol. 284, no. 18, pp. 12512–12523, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. V. Iotsova, J. Caamaño, J. Loy, Y. Yang, A. Lewin, and R. Bravo, “Osteopetrosis in mice lacking NF-κB1 and NF-κB2,” Nature Medicine, vol. 3, no. 11, pp. 1285–1289, 1997. View at Scopus
  90. K. Strait, Y. Li, D. L. Dillehay, and M. N. Weitzmann, “Suppression of NF-κB activation blocks osteoclastic bone resorption during estrogen deficiency,” International Journal of Molecular Medicine, vol. 21, no. 4, pp. 521–525, 2008. View at Scopus
  91. R. Feng, G. Anderson, G. Xiao et al., “SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-κB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth,” Blood, vol. 109, no. 5, pp. 2130–2138, 2007. View at Publisher · View at Google Scholar · View at Scopus
  92. J. C. Clohisy, T. Hirayama, E. Frazier, S. K. Han, and Y. Abu-Amer, “NF-κB signaling blockade abolishes implant particle-induced osteoclastogenesis,” Journal of Orthopaedic Research, vol. 22, no. 1, pp. 13–20, 2004. View at Publisher · View at Google Scholar · View at Scopus
  93. S. Dai, T. Hirayama, S. Abbas, and Y. Abu-Amer, “The IκB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis,” Journal of Biological Chemistry, vol. 279, no. 36, pp. 37219–37222, 2004. View at Publisher · View at Google Scholar · View at Scopus
  94. X. Lu, P. Farmer, J. Rubin, and M. S. Nanes, “Integration of the NfκB p65 subunit into the vitamin D receptor transcriptional complex: identification of p65 domains that inhibit 1,25-dihydroxyvitamin D3-stimulated transcription,” Journal of Cellular Biochemistry, vol. 92, no. 4, pp. 833–848, 2004. View at Publisher · View at Google Scholar · View at Scopus
  95. L. Gilbert, X. He, P. Farmer et al., “Inhibition of osteoblast differentiation by tumor necrosis factor-α,” Endocrinology, vol. 141, no. 11, pp. 3956–3964, 2000. View at Scopus
  96. M. S. Nanes, “Tumor necrosis factor-κ: molecular and cellular mechanisms in skeletal pathology,” Gene, vol. 321, no. 1-2, pp. 1–15, 2003. View at Publisher · View at Google Scholar · View at Scopus
  97. E. C. Wahl, J. Aronson, L. Liu et al., “Restoration of regenerative osteoblastogenesis in aged mice: modulation of TNF,” Journal of Bone and Mineral Research, vol. 25, no. 1, pp. 114–123, 2010. View at Publisher · View at Google Scholar · View at Scopus
  98. Y. Li, A. Li, K. Strait, H. Zhang, M. S. Nanes, and M. N. Weitzmann, “Endogenous TNFα lowers maximum peak bone mass and inhibits osteoblastic smad activation through NF-κB,” Journal of Bone and Mineral Research, vol. 22, no. 5, pp. 646–655, 2007. View at Publisher · View at Google Scholar · View at Scopus
  99. M. Wan and X. Cao, “BMP signaling in skeletal development,” Biochemical and Biophysical Research Communications, vol. 328, no. 3, pp. 651–657, 2005. View at Publisher · View at Google Scholar · View at Scopus
  100. E. J. Moerman, K. Teng, D. A. Lipschitz, and B. Lecka-Czernik, “Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-γ2 transcription factor and TGF-β/BMP signaling pathways,” Aging Cell, vol. 3, no. 6, pp. 379–389, 2004. View at Publisher · View at Google Scholar · View at Scopus
  101. F. Zhang, T. Qiu, X. Wu et al., “Sustained BMP signaling in osteoblasts stimulates bone formation by promoting angiogenesis and osteoblast differentiation,” Journal of Bone and Mineral Research, vol. 24, no. 7, pp. 1224–1233, 2009. View at Publisher · View at Google Scholar · View at Scopus
  102. S. D. Boden, “The ABCs of BMPs,” Orthop Nurs, vol. 24, pp. 49–52, 2005.
  103. K. Janssens, P. Ten Dijke, S. Janssens, and W. Van Hul, “Transforming growth factor-β1 to the bone,” Endocrine Reviews, vol. 26, no. 6, pp. 743–774, 2005. View at Publisher · View at Google Scholar · View at Scopus
  104. Y. Tang, X. Wu, W. Lei et al., “TGF-β1-induced migration of bone mesenchymal stem cells couples bone resorption with formation,” Nature Medicine, vol. 15, no. 7, pp. 757–765, 2009. View at Publisher · View at Google Scholar · View at Scopus
  105. N. Selvamurugan, S. Kwok, T. Alliston, M. Reiss, and N. C. Partridge, “Transforming growth factor-β1 regulation of collagenase-3 expression in osteoblastic cells by cross-talk between the Smad and MAPK signaling pathways and their components, Smad2 and Runx2,” Journal of Biological Chemistry, vol. 279, no. 18, pp. 19327–19334, 2004. View at Publisher · View at Google Scholar · View at Scopus
  106. S. Spinella-Jaegle, S. Roman-Roman, C. Faucheu et al., “Opposite effects of bone morphogenetic protein-2 and transforming growth factor-β1 on osteoblast differentiation,” Bone, vol. 29, no. 4, pp. 323–330, 2001. View at Publisher · View at Google Scholar · View at Scopus
  107. J. Gebken, A. Feydt, J. Brinckmann, H. Notbohm, P. K. Müller, and B. Bätge, “Ligand-induced downregulation of receptors for TGF-β in human osteoblast-like cells from adult donors,” Journal of Endocrinology, vol. 161, no. 3, pp. 503–510, 1999. View at Publisher · View at Google Scholar · View at Scopus
  108. Y. Takeuchi, M. Suzawa, T. Kikuchi, E. Nishida, T. Fujita, and T. Matsumoto, “Differentiation and transforming growth factor-β receptor down-regulation by collagen-α2β1 integrin interaction is mediated by focal adhesion kinase and its downstream signals in murine osteoblastic cells,” Journal of Biological Chemistry, vol. 272, no. 46, pp. 29309–29316, 1997. View at Publisher · View at Google Scholar · View at Scopus
  109. R. A. Eliseev, E. M. Schwarz, M. J. Zuscik, R. J. O'Keefe, H. Drissi, and R. N. Rosier, “Smad7 mediates inhibition of Saos2 osteosarcoma cell differentiation by NFκB,” Experimental Cell Research, vol. 312, no. 1, pp. 40–50, 2006. View at Publisher · View at Google Scholar · View at Scopus
  110. R. Guo, M. Yamashita, Q. Zhang et al., “Ubiquitin ligase Smurf1 mediates tumor necrosis factor-induced systemic bone loss by promoting proteasomal degradation of bone morphogenetic signaling proteins,” Journal of Biological Chemistry, vol. 283, no. 34, pp. 23084–23092, 2008. View at Publisher · View at Google Scholar · View at Scopus
  111. T. Mukai, F. Otsuka, H. Otani et al., “TNF-α inhibits BMP-induced osteoblast differentiation through activating SAPK/JNK signaling,” Biochemical and Biophysical Research Communications, vol. 356, no. 4, pp. 1004–1010, 2007. View at Publisher · View at Google Scholar · View at Scopus
  112. M. Yamaguchi and M. N. Weitzmann, “The estrogen 17β-estradiol and phytoestrogen genistein mediate differential effects on osteoblastic NF-κB activity,” International Journal of Molecular Medicine, vol. 23, no. 2, pp. 297–301, 2009. View at Publisher · View at Google Scholar · View at Scopus
  113. J. Chang, Z. Wang, E. Tang et al., “Inhibition of osteoblastic bone formation by nuclear factor-κB,” Nature Medicine, vol. 15, no. 6, pp. 682–689, 2009. View at Publisher · View at Google Scholar · View at Scopus
  114. M. Yamaguchi and M. N. Weitzmann, “Vitamin K2 stimulates osteoblastogenesis and suppresses osteoclastogenesis by suppressing NF-κB activation,” International Journal of Molecular Medicine, vol. 27, no. 1, pp. 3–14, 2011. View at Publisher · View at Google Scholar · View at Scopus
  115. M. Yamaguchi, J. L. Arbiser, and M. N. Weitzmann, “Honokiol stimulates osteoblastogenesis by suppressing NF-κB activation,” International Journal of Molecular Medicine, vol. 28, pp. 1049–1053, 2011.
  116. M. Yamaguchi and M. N. Weitzmann, “Zinc stimulates osteoblastogenesis and suppresses osteoclastogenesis by antagonizing NF-κB activation,” Molecular and Cellular Biochemistry, vol. 355, pp. 179–186, 2011.
  117. M. Yamaguchi and M. N. Weitzmann, “The bone anabolic carotenoids p-hydroxycinnamic acid and β-cryptoxanthin antagonize NF-κB activation in MC3T3 preosteoblasts,” Molecular Medicine Reports, vol. 2, no. 4, pp. 641–644, 2009. View at Publisher · View at Google Scholar · View at Scopus
  118. M. Yamaguchi and M. N. Weitzmann, “The bone anabolic carotenoid p-hydroxycinnamic acid promotes osteoblast mineralization and suppresses osteoclast differentiation by antagonizing NF-κB activation,” International Journal of Molecular Medicine, vol. 30, no. 3, pp. 708–712, 2012. View at Publisher · View at Google Scholar
  119. J. Xiong, M. Onal, R. L. Jilka, R. S. Weinstein, S. C. Manolagas, and C. A. O'Brien, “Matrix-embedded cells control osteoclast formation,” Nature Medicine, vol. 17, pp. 1235–1241, 2011.
  120. D. A. Corral, M. Amling, M. Priemel et al., “Dissociation between bone resorption and bone formation in osteopenic transgenic mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 23, pp. 13835–13840, 1998. View at Publisher · View at Google Scholar · View at Scopus
  121. M. C. Horowitz, A. L. M. Bothwell, D. G. T. Hesslein, D. L. Pflugh, and D. G. Schatz, “B cells and osteoblast and osteoclast development,” Immunological Reviews, vol. 208, pp. 141–153, 2005. View at Scopus
  122. M. Onal, J. Xiong, X. Chen et al., “Receptor activator of nuclear factor kappaB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss,” The Journal of Biological Chemistry, vol. 287, pp. 29851–29860, 2012.
  123. T. Nakashima, M. Hayashi, T. Fukunaga et al., “Evidence for osteocyte regulation of bone homeostasis through RANKL expression,” Nature Medicine, vol. 17, pp. 1231–1234, 2011. View at Publisher · View at Google Scholar
  124. M. N. Weitzmann, S. Cenci, L. Rifas, J. Haug, J. Dipersio, and R. Pacifici, “T cell activation induces human osteoclast formation via receptor activator of nuclear factor κB ligand-dependent and -independent mechanisms,” Journal of Bone and Mineral Research, vol. 16, no. 2, pp. 328–337, 2001. View at Scopus
  125. M. N. Weitzmann, S. Cenci, L. Rifas, C. Brown, and R. Pacifici, “Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines,” Blood, vol. 96, no. 5, pp. 1873–1878, 2000. View at Scopus
  126. L. Rifas and M. N. Weitzmann, “A novel T cell cytokine, secreted osteoclastogenic factor of activated T cells, induces osteoclast formation in a RANKL-independent manner,” Arthritis and Rheumatism, vol. 60, no. 11, pp. 3324–3335, 2009. View at Publisher · View at Google Scholar · View at Scopus
  127. L. Rifas, R. Civitelli, and L. V. Avioli, “Activated T cells stimulate IL-6 production by human osteoblasts via soluble factors and cell contact,” Journal of Bone and Mineral Research, vol. 12, p. S436, 1998.
  128. J. R. Edwards, S. G. Sun, R. Locklin et al., “LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis,” Arthritis and Rheumatism, vol. 54, no. 5, pp. 1451–1462, 2006. View at Publisher · View at Google Scholar · View at Scopus
  129. D. M. Shinar and G. A. Rodan, “Biphasic effects of transforming growth factor-β on the production of osteoclast-like cells in mouse bone marrow cultures: the role of prostaglandins in the generation of these cells,” Endocrinology, vol. 126, no. 6, pp. 3153–3158, 1990. View at Scopus
  130. R. J. Sells Galvin, C. L. Gatlin, J. W. Horn, and T. R. Fuson, “TGF-β enhances osteoclast differentiation in hematopoietic cell cultures stimulated with RANKL and M-CSF,” Biochemical and Biophysical Research Communications, vol. 265, no. 1, pp. 233–239, 1999. View at Publisher · View at Google Scholar · View at Scopus
  131. N. J. Horwood, V. Kartsogiannis, J. M. W. Quinn, E. Romas, T. J. Martin, and M. T. Gillespie, “Activated T lymphocytes support osteoclast formation in vitro,” Biochemical and Biophysical Research Communications, vol. 265, no. 1, pp. 144–150, 1999. View at Publisher · View at Google Scholar · View at Scopus
  132. C. Chenu, J. Pfeilschifter, G. R. Mundy, and G. D. Roodman, “Transforming growth factor β inhibits formation of osteoclast-like cells in long-term human marrow cultures,” Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 15, pp. 5683–5687, 1988. View at Scopus
  133. D. E. Hughes, A. Dai, J. C. Tiffee, H. H. Li, G. R. Munoy, and B. F. Boyce, “Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β,” Nature Medicine, vol. 2, no. 10, pp. 1132–1135, 1996. View at Publisher · View at Google Scholar · View at Scopus
  134. M. N. Weitzmann, S. Cenci, J. Haug, C. Brown, J. DiPersio, and R. Pacifici, “B lymphocytes inhibit human osteoclastogenesis by secretion of TGFbeta,” Journal of Cellular Biochemistry, vol. 78, pp. 318–324, 2000.
  135. H. Takai, M. Kanematsu, K. Yano et al., “Transforming growth factor-β stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells,” Journal of Biological Chemistry, vol. 273, no. 42, pp. 27091–27096, 1998. View at Publisher · View at Google Scholar · View at Scopus
  136. J. M. W. Quinn, K. Itoh, N. Udagawa et al., “Transforming growth factor β affects osteoclast differentiation via direct and indirect actions,” Journal of Bone and Mineral Research, vol. 16, no. 10, pp. 1787–1794, 2001. View at Scopus
  137. Y. Gao, W. P. Qian, K. Dark et al., “Estrogen prevents bone loss through transforming growth factor β signaling in T cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 47, pp. 16618–16623, 2004. View at Publisher · View at Google Scholar · View at Scopus
  138. I. Itonaga, A. Sabokbar, S. G. Sun et al., “Transforming growth factor-β induces osteoclast formation in the absence of RANKL,” Bone, vol. 34, no. 1, pp. 57–64, 2004. View at Publisher · View at Google Scholar · View at Scopus
  139. T. J. Yun, P. M. Chaudhary, G. L. Shu et al., “OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40,” Journal of Immunology, vol. 161, no. 11, pp. 6113–6121, 1998. View at Scopus
  140. Y. Li, G. Toraldo, A. Li et al., “B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo,” Blood, vol. 109, no. 9, pp. 3839–3848, 2007. View at Publisher · View at Google Scholar · View at Scopus
  141. D. Grcevic, S. K. Lee, A. Marusic, and J. A. Lorenzo, “Depletion of CD4 and CD8 T lymphocytes in mice in vivo enhances 1,25-dihydroxyvitamin D3-stimulated osteoclast-like cell formation in vitro by a mechanism that is dependent on prostaglandin synthesis,” Journal of Immunology, vol. 165, no. 8, pp. 4231–4238, 2000. View at Scopus
  142. E. Lopez-Granados, S. T. Temmerman, L. Wu et al., “Osteopenia in X-linked hyper-IgM syndrome reveals a regulatory role for CD40 ligand in osteoclastogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 12, pp. 5056–5061, 2007. View at Publisher · View at Google Scholar · View at Scopus
  143. P. Tebas, W. G. Powderly, S. Claxton et al., “Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy,” AIDS, vol. 14, no. 4, pp. F63–F67, 2000. View at Publisher · View at Google Scholar · View at Scopus
  144. K. Mondy and P. Tebas, “Emerging bone problems in patients infected with human immunodeficiency virus,” Clinical Infectious Diseases, vol. 36, no. 2, pp. S101–S105, 2003. View at Publisher · View at Google Scholar · View at Scopus
  145. K. Mondy, K. Yarasheski, W. G. Powderly et al., “Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals,” Clinical Infectious Diseases, vol. 36, no. 4, pp. 482–490, 2003. View at Publisher · View at Google Scholar · View at Scopus
  146. J. S. Huang, S. J. Wilkie, M. P. Sullivan, and S. Grinspoon, “Reduced bone density in androgen-deficient women with acquired immune deficiency syndrome wasting,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 8, pp. 3533–3539, 2001. View at Publisher · View at Google Scholar · View at Scopus
  147. M. J. Bolland and A. Grey, “HIV and low bone density: responsible party, or guilty by association?” IBMS BoneKEy, vol. 8, pp. 7–15, 2011. View at Publisher · View at Google Scholar
  148. S. E. Dolan, J. S. Huang, K. M. Killilea, M. P. Sullivan, N. Aliabadi, and S. Grinspoon, “Reduced bone density in HIV-infected women,” AIDS, vol. 18, no. 3, pp. 475–483, 2004. View at Publisher · View at Google Scholar · View at Scopus
  149. J. Thomas and S. M. Doherty, “HIV infection—a risk factor for osteoporosis,” Journal of Acquired Immune Deficiency Syndromes, vol. 33, no. 3, pp. 281–291, 2003. View at Scopus
  150. G. A. McComsey, P. Tebas, E. Shane et al., “Bone disease in HIV infection: a practical review and recommendations for HIV care providers,” Clinical Infectious Diseases, vol. 51, no. 8, pp. 937–946, 2010. View at Publisher · View at Google Scholar · View at Scopus
  151. T. T. Brown and R. B. Qaqish, “Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review,” AIDS, vol. 20, no. 17, pp. 2165–2174, 2006. View at Publisher · View at Google Scholar · View at Scopus
  152. S. L. Hui, C. W. Slemenda, and C. C. Johnston, “Age and bone mass as predictors of fracture in a prospective study,” Journal of Clinical Investigation, vol. 81, no. 6, pp. 1804–1809, 1988. View at Scopus
  153. World Health Organization, “Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group,” World Health Organization Technical Report Series, vol. 843, pp. 1–129, 1994.
  154. S. H. Abbasi-Jahromi, A. Matayoshi, R. Kimble, A. Dimarogonas, and R. Pacifici, “Bone quality factor analysis: a new noninvasive technique for the measurement of bone density and bone strength,” Journal of Bone and Mineral Research, vol. 11, no. 5, pp. 594–599, 1996. View at Scopus
  155. V. Amorosa and P. Tebas, “Bone disease and HIV infection,” Clinical Infectious Diseases, vol. 42, no. 1, pp. 108–114, 2006. View at Publisher · View at Google Scholar · View at Scopus
  156. G. Guaraldi, P. Ventura, M. Albuzza et al., “Pathological fractures in AIDS patients with osteopenia and osteoporosis induced by antiretroviral therapy,” AIDS, vol. 15, no. 1, pp. 137–138, 2001. View at Publisher · View at Google Scholar · View at Scopus
  157. V. A. Triant, T. T. Brown, H. Lee, and S. K. Grinspoon, “Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 9, pp. 3499–3504, 2008. View at Publisher · View at Google Scholar · View at Scopus
  158. J. H. Arnsten, R. Freeman, A. A. Howard, M. Floris-Moore, Y. Lo, and R. S. Klein, “Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection,” AIDS, vol. 21, no. 5, pp. 617–623, 2007. View at Publisher · View at Google Scholar · View at Scopus
  159. J. Prior, D. Burdge, E. Maan et al., “Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study,” Osteoporosis International, vol. 18, no. 10, pp. 1345–1353, 2007. View at Publisher · View at Google Scholar · View at Scopus
  160. J. A. Womack, J. L. Goulet, C. Gibert et al., “Increased risk of fragility fractures among HIV infected compared to uninfected male veterans,” PLoS ONE, vol. 6, no. 2, Article ID e17217, 2011. View at Publisher · View at Google Scholar · View at Scopus
  161. B. Young, C. N. Dao, K. Buchacz, R. Baker, and J. T. Brooks, “Increased rates of bone fracture among HIV-infected persons in the HIV outpatient study (HOPS) compared with the US general population, 2000-2006,” Clinical Infectious Diseases, vol. 52, no. 8, pp. 1061–1068, 2011. View at Publisher · View at Google Scholar · View at Scopus
  162. M. T. Yin, Q. Shi, D. R. Hoover et al., “Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study,” AIDS, vol. 24, no. 17, pp. 2679–2686, 2010. View at Publisher · View at Google Scholar · View at Scopus
  163. S. Desai and A. Landay, “Early immune senescence in HIV disease,” Current HIV/AIDS Reports, vol. 7, no. 1, pp. 4–10, 2010. View at Publisher · View at Google Scholar · View at Scopus
  164. A. De Milito, “B lymphocyte dysfunctions in HIV infection,” Current HIV Research, vol. 2, no. 1, pp. 11–21, 2004. View at Publisher · View at Google Scholar · View at Scopus
  165. S. Moir, J. Ho, A. Malaspina et al., “Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals,” The Journal of Experimental Medicine, vol. 205, no. 8, pp. 1797–1805, 2008. View at Publisher · View at Google Scholar · View at Scopus
  166. M. Morrow, A. Valentin, R. Little, R. Yarchoan, and G. N. Pavlakis, “A splenic marginal zone-like peripheral blood CD27+B220 B cell population is preferentially depleted in HIV type 1-infected individuals,” AIDS Research and Human Retroviruses, vol. 24, no. 4, pp. 621–633, 2008. View at Publisher · View at Google Scholar · View at Scopus
  167. W. Reid, M. Sadowska, F. Denaro et al., “An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 16, pp. 9271–9276, 2001. View at Publisher · View at Google Scholar · View at Scopus
  168. N. Manabe, H. Kawaguchi, H. Chikuda et al., “Connection between B lymphocyte and osteoclast differentiation pathways,” Journal of Immunology, vol. 167, no. 5, pp. 2625–2631, 2001. View at Scopus
  169. T. Kawai, T. Matsuyama, Y. Hosokawa et al., “B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease,” American Journal of Pathology, vol. 169, no. 3, pp. 987–998, 2006. View at Publisher · View at Google Scholar · View at Scopus
  170. M. Kanematsu, T. Sato, H. Takai, K. Watanabe, K. Ikeda, and Y. Yamada, “Prostaglandin E2 induces expression of receptor activator of nuclear factor-κB ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency,” Journal of Bone and Mineral Research, vol. 15, no. 7, pp. 1321–1329, 2000. View at Scopus
  171. T. Vikulina, X. Fan, M. Yamaguchi et al., “Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 31, pp. 13848–13853, 2010. View at Publisher · View at Google Scholar · View at Scopus
  172. S. G. Deeks, “HIV infection, inflammation, immunosenescence, and aging,” Annual Review of Medicine, vol. 62, pp. 141–155, 2011. View at Publisher · View at Google Scholar · View at Scopus
  173. S. G. Deeks, “Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy,” Topics in HIV Medicine, vol. 17, no. 4, pp. 118–123, 2009. View at Scopus
  174. J. M. Brenchley, D. A. Price, T. W. Schacker et al., “Microbial translocation is a cause of systemic immune activation in chronic HIV infection,” Nature Medicine, vol. 12, no. 12, pp. 1365–1371, 2006. View at Publisher · View at Google Scholar · View at Scopus
  175. W. Zou and Z. Bar-Shavit, “Dual modulation of osteoclast differentiation by lipopolysaccharide,” Journal of Bone and Mineral Research, vol. 17, no. 7, pp. 1211–1218, 2002. View at Scopus
  176. C. Duvivier, S. Kolta, L. Assoumou et al., “Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients,” AIDS, vol. 23, no. 7, pp. 817–824, 2009. View at Publisher · View at Google Scholar · View at Scopus
  177. A. B. Hansen, N. Obel, H. Nielsen, C. Pedersen, and J. Gerstoft, “Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial,” HIV Medicine, vol. 12, no. 3, pp. 157–165, 2011. View at Publisher · View at Google Scholar · View at Scopus
  178. K. Briot, S. Kolta, P. Flandre et al., “Prospective one-year bone loss in treatment-naïve HIV+ men and women on single or multiple drug HIV therapies,” Bone, vol. 48, pp. 1133–1139, 2011. View at Publisher · View at Google Scholar
  179. M. G. A. van Vonderen, P. Lips, M. A. van Agtmael et al., “First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir,” AIDS, vol. 23, no. 11, pp. 1367–1376, 2009. View at Publisher · View at Google Scholar · View at Scopus
  180. P. Rivas, M. Górgolas, R. García-Delgado, M. Díaz-Curiel, A. Goyenechea, and M. L. Fernández-Guerrero, “Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir,” HIV Medicine, vol. 9, no. 2, pp. 89–95, 2008. View at Publisher · View at Google Scholar · View at Scopus
  181. J. Fernández-Rivera, R. García, F. Lozano et al., “Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients,” HIV Clinical Trials, vol. 4, no. 5, pp. 337–346, 2003. View at Publisher · View at Google Scholar · View at Scopus
  182. M. W. H. Wang, S. Wei, R. Faccio et al., “The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling,” Journal of Clinical Investigation, vol. 114, no. 2, pp. 206–213, 2004. View at Publisher · View at Google Scholar · View at Scopus
  183. J. M. Fakruddin and J. Laurence, “HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor κB ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-γ/RANKL cross-talk,” Journal of Biological Chemistry, vol. 278, no. 48, pp. 48251–48258, 2003. View at Publisher · View at Google Scholar · View at Scopus
  184. D. P. Wanner, A. Tyndall, and U. A. Walker, “Tenofovir-induced osteomalacia,” Clinical and Experimental Rheumatology, vol. 27, no. 6, pp. 1001–1003, 2009. View at Scopus
  185. G. Pan, X. Wu, M. A. McKenna, X. Feng, T. R. Nagy, and J. M. McDonald, “AZT enhances osteoclastogenesis and bone loss,” AIDS Research and Human Retroviruses, vol. 20, no. 6, pp. 608–620, 2004. View at Publisher · View at Google Scholar · View at Scopus
  186. G. Pan, M. Kilby, and J. M. McDonald, “Modulation of osteoclastogenesis induced by nucleoside reverse transcriptase inhibitors,” AIDS Research and Human Retroviruses, vol. 22, no. 11, pp. 1131–1141, 2006. View at Publisher · View at Google Scholar · View at Scopus
  187. T. T. Brown, G. A. McComsey, M. S. King, R. B. Qaqish, B. M. Bernstein, and B. A. Da Silva, “Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen,” Journal of Acquired Immune Deficiency Syndromes, vol. 51, no. 5, pp. 554–561, 2009. View at Publisher · View at Google Scholar · View at Scopus
  188. D. Bruera, N. Luna, D. O. David, L. M. Bergoglio, and J. Zamudio, “Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy,” AIDS, vol. 17, no. 13, pp. 1917–1923, 2003. View at Publisher · View at Google Scholar · View at Scopus
  189. J. E. Gallant, S. Staszewski, A. L. Pozniak et al., “Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial,” Journal of the American Medical Association, vol. 292, no. 2, pp. 191–201, 2004. View at Publisher · View at Google Scholar · View at Scopus
  190. H. J. Stellbrink, C. Orkin, J. R. Arribas et al., “Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study,” Clinical Infectious Diseases, vol. 51, no. 8, pp. 963–972, 2010. View at Publisher · View at Google Scholar · View at Scopus
  191. J. M. Franco, A. Rubio, M. Martínez-Moya et al., “T-cell repopulation and thymic volume in HIV-1-infected adult patients after highly active antiretroviral therapy,” Blood, vol. 99, no. 10, pp. 3702–3706, 2002. View at Publisher · View at Google Scholar · View at Scopus
  192. R. C. Kalayjian, J. Spritzler, M. Pu et al., “Distinct mechanisms of T cell reconstitution can be identified by estimating thymic volume in adult HIV-1 disease,” Journal of Infectious Diseases, vol. 192, no. 9, pp. 1577–1587, 2005. View at Publisher · View at Google Scholar · View at Scopus
  193. M. R. Ryan, R. Shepherd, J. K. Leavey et al., “An IL-7-dependent rebound in thymic T cell output contributes to the bone loss induced by estrogen deficiency,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 46, pp. 16735–16740, 2005. View at Publisher · View at Google Scholar · View at Scopus
  194. J. Wactawski-Wende, S. G. Grossi, M. Trevisan et al., “The role of osteopenia in oral bone loss and periodontal disease,” Journal of Periodontology, vol. 67, no. 10, pp. 1076–1084, 1996. View at Scopus
  195. B. Klausen, H. P. Hougen, and N. E. Fiehn, “Increased periodontal bone loss in temporarily B lymphocyte-deficient rats,” Journal of Periodontal Research, vol. 24, no. 6, pp. 384–390, 1989. View at Scopus
  196. Y. Choi and J. J. Kim, “B cells activated in the presence of Th1 cytokines inhibit osteoclastogenesis,” Experimental and Molecular Medicine, vol. 35, no. 5, pp. 385–392, 2003. View at Scopus
  197. M. A. Taubman and T. Kawai, “Involvement of T-lymphocytes in periodontal disease and in direct and indirect induction of bone resorption,” Critical Reviews in Oral Biology and Medicine, vol. 12, no. 2, pp. 125–135, 2001. View at Scopus
  198. T. Crotti, M. D. Smith, R. Hirsch et al., “Receptor activator NF κB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis,” Journal of Periodontal Research, vol. 38, no. 4, pp. 380–387, 2003. View at Scopus
  199. G. Brunetti, S. Colucci, P. Pignataro et al., “T cells support osteoclastogenesis in an in vitro model derived from human periodontitis patients,” Journal of Periodontology, vol. 76, no. 10, pp. 1675–1680, 2005. View at Publisher · View at Google Scholar · View at Scopus
  200. S. Colucci, G. Mori, G. Brunetti et al., “Interleukin-7 production by B lymphocytes affects the T cell-dependent osteoclast formation in an in vitro model derived from human periodontitis patients,” International Journal of Immunopathology and Pharmacology, vol. 18, no. 3, pp. 13–19, 2005. View at Scopus
  201. G. Mori, G. Brunetti, S. Collucci et al., “Osteoblast apoptosis in periodontal disease: role of TNF-related apoptosis-inducing ligand,” International Journal of Immunopathology and Pharmacology, vol. 22, no. 1, pp. 95–103, 2009. View at Scopus
  202. M. Feldmann, F. M. Brennan, and R. N. Maini, “Rheumatoid arthritis,” Cell, vol. 85, no. 3, pp. 307–310, 1996. View at Publisher · View at Google Scholar · View at Scopus
  203. J. C. W. Edwards, L. Szczepański, J. Szechiński et al., “Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis,” The New England Journal of Medicine, vol. 350, no. 25, pp. 2572–2581, 2004. View at Publisher · View at Google Scholar · View at Scopus
  204. G. Schett and J. P. David, “The multiple faces of autoimmune-mediated bone loss,” Nature Reviews Endocrinology, vol. 6, no. 12, pp. 698–706, 2010. View at Publisher · View at Google Scholar · View at Scopus
  205. C. Fournier, “Where do T cells stand in rheumatoid arthritis?” Joint Bone Spine, vol. 72, no. 6, pp. 527–532, 2005. View at Publisher · View at Google Scholar · View at Scopus
  206. Y. Y. Kong, U. Felge, I. Sarosi et al., “Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand,” Nature, vol. 402, no. 6759, pp. 304–309, 1999. View at Publisher · View at Google Scholar · View at Scopus
  207. X. He, A. H. Kang, and J. M. Stuart, “Anti-human type II collagen CD19+ B cells are present in patients with rheumatoid arthritis and healthy individuals,” Journal of Rheumatology, vol. 28, no. 10, pp. 2168–2175, 2001. View at Scopus
  208. K. Yanaba, Y. Hamaguchi, G. M. Venturi, D. A. Steeber, S. Clair, and T. F. Tedder, “B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity,” Journal of Immunology, vol. 179, no. 2, pp. 1369–1380, 2007. View at Scopus
  209. P. Li and E. M. Schwarz, “The TNF-α transgenic mouse model of inflammatory arthritis,” Springer Seminars in Immunopathology, vol. 25, no. 1, pp. 19–33, 2003. View at Publisher · View at Google Scholar · View at Scopus
  210. G. Schett, K. Redlich, S. Hayer et al., “Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice,” Arthritis and Rheumatism, vol. 48, no. 7, pp. 2042–2051, 2003. View at Publisher · View at Google Scholar · View at Scopus
  211. R. Fleischmann, I. Iqbal, P. Nandeshwar, and A. Quiceno, “Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept,” Drug Safety, vol. 25, no. 3, pp. 173–197, 2002. View at Scopus
  212. J. K. Jenkins and K. J. Hardy, “Biological modifier therapy for the treatment of rheumatoid arthritis,” American Journal of the Medical Sciences, vol. 323, no. 4, pp. 197–205, 2002. View at Scopus
  213. A. M. Reimold, “TNFalpha as therapeutic target: new drugs, more applications,” Current Drug Targets: Inflammation & Allergy, vol. 1, pp. 377–392, 2002.
  214. N. T. Ilowite, “Update on biologics in juvenile idiopathic arthritis,” Current Opinion in Rheumatology, vol. 20, no. 5, pp. 613–618, 2008. View at Publisher · View at Google Scholar · View at Scopus
  215. M. Natsumeda, K. Nishiya, and Z. Ota, “Stimulation by interleukin-7 of mononuclear cells in peripheral blood, synovial fluid and synovial tissue from patients with rheumatoid arthritis,” Acta Medica Okayama, vol. 47, no. 6, pp. 391–397, 1993. View at Scopus
  216. F. De Benedetti, M. Massa, P. Pignatti, M. Kelley, C. R. Faltynek, and A. Martini, “Elevated circulating interleukin-7 levels in patients with systemic juvenile rheumatoid arthritis,” Journal of Rheumatology, vol. 22, no. 8, pp. 1581–1585, 1995. View at Scopus
  217. L. Leistad, M. Østensen, and A. Faxvaag, “Detection of cytokine mRNA in human, articular cartilage from patients with rheumatoid arthritis and osteoarthritis by reverse transcriptase-polymerase chain reaction,” Scandinavian Journal of Rheumatology, vol. 27, no. 1, pp. 61–67, 1998. View at Publisher · View at Google Scholar · View at Scopus
  218. S. Harada, M. Yamamura, H. Okamoto et al., “Production of interleukin-7 and interleukin-15 by fibroblast-like synoviocytes from patients with rheumatoid arthritis,” Arthritis & Rheumatism, vol. 42, pp. 1508–1516, 1999.
  219. S. Colucci, G. Brunetti, F. P. Cantatore et al., “Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFα, and IL-7 in an in vitro model derived from human psoriatic arthritis,” Journal of Pathology, vol. 212, no. 1, pp. 47–55, 2007. View at Publisher · View at Google Scholar · View at Scopus
  220. S. M. Churchman and F. Ponchel, “Interleukin-7 in rheumatoid arthritis,” Rheumatology, vol. 47, no. 6, pp. 753–759, 2008. View at Publisher · View at Google Scholar · View at Scopus
  221. S. A. Y. Hartgring, C. R. Willis, D. Alcorn et al., “Blockade of the interleukin-7 receptor inhibits collagen-induced arthritis and is associated with reduction of T cell activity and proinflammatory mediators,” Arthritis and Rheumatism, vol. 62, no. 9, pp. 2716–2725, 2010. View at Publisher · View at Google Scholar · View at Scopus
  222. E. Lubberts, “IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis?” Cytokine, vol. 41, no. 2, pp. 84–91, 2008. View at Publisher · View at Google Scholar · View at Scopus
  223. S. Kotake, N. Udagawa, N. Takahashi et al., “IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis,” Journal of Clinical Investigation, vol. 103, no. 9, pp. 1345–1352, 1999. View at Scopus
  224. E. Lubberts, L. Van den Bersselaar, B. Oppers-Walgreen et al., “IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-κB ligand/osteoprotegerin balance1,” Journal of Immunology, vol. 170, no. 5, pp. 2655–2662, 2003. View at Scopus
  225. K. Zwerina, M. Koenders, A. Hueber et al., “Anti IL-17A therapy inhibits bone loss in TNF-α-mediated murine arthritis by modulation of the T-cell balance,” European Journal of Immunology, vol. 42, no. 2, pp. 413–423, 2012. View at Publisher · View at Google Scholar
  226. B. L. Riggs, S. Khosla, and L. J. Melton, “Sex steroids and the construction and conservation of the adult skeleton,” Endocrine Reviews, vol. 23, no. 3, pp. 279–302, 2002. View at Publisher · View at Google Scholar · View at Scopus
  227. J. A. Clowes, B. L. Riggs, and S. Khosla, “The role of the immune system in the pathophysiology of osteoporosis,” Immunological Reviews, vol. 208, pp. 207–227, 2005. View at Publisher · View at Google Scholar · View at Scopus
  228. C. Roggia, Y. Gao, S. Cenci et al., “Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 24, pp. 13960–13965, 2001. View at Publisher · View at Google Scholar · View at Scopus
  229. S. Cenci, G. Toraldo, M. N. Weitzmann et al., “Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-γ-induced class II transactivator,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 18, pp. 10405–10410, 2003. View at Publisher · View at Google Scholar · View at Scopus
  230. M. N. Weitzmann and R. Pacifici, “Role of the immune system in postmenopausal bone loss,” Current Osteoporosis Reports, vol. 3, no. 3, pp. 92–97, 2005. View at Scopus
  231. M. N. Weitzmann and R. Pacifici, “Estrogen regulation of immune cell bone interactions,” Annals of the New York Academy of Sciences, vol. 1068, no. 1, pp. 256–274, 2006. View at Publisher · View at Google Scholar · View at Scopus
  232. Y. Gao, F. Grassi, M. R. Ryan et al., “IFN-γ stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation,” Journal of Clinical Investigation, vol. 117, no. 1, pp. 122–132, 2007. View at Publisher · View at Google Scholar · View at Scopus
  233. F. Grassi, G. Tell, M. Robbie-Ryan et al., “Oxidative stress causes bone loss in estrogen-deficient mice through enhanced bone marrow dendritic cell activation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 38, pp. 15087–15092, 2007. View at Publisher · View at Google Scholar · View at Scopus
  234. M. N. Weitzmann and R. Pacifici, “T cells: unexpected players in the bone loss induced by estrogen deficiency and in basal bone homeostasis,” Annals of the New York Academy of Sciences, vol. 1116, pp. 360–375, 2007. View at Publisher · View at Google Scholar · View at Scopus
  235. J. Y. Li, H. Tawfeek, B. Bedi et al., “Ovariectomy disregulates osteoblast and osteoclast formation through the T-cell receptor CD40 ligand,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 2, pp. 768–773, 2011. View at Publisher · View at Google Scholar · View at Scopus
  236. T. Masuzawa, C. Miyaura, Y. Onoe et al., “Estrogen deficiency stimulates B lymphopoiesis in mouse bone marrow,” Journal of Clinical Investigation, vol. 94, no. 3, pp. 1090–1097, 1994. View at Scopus
  237. M. C. Erlandsson, C. A. Jonsson, U. Islander, C. Ohlsson, and H. Carlsten, “Oestrogen receptor specificity in oestradiol-mediated effects on B lymphopoiesis and immunoglobulin production in male mice,” Immunology, vol. 108, no. 3, pp. 346–351, 2003. View at Publisher · View at Google Scholar · View at Scopus
  238. C. Miyaura, Y. Onoe, M. Inada et al., “Increased B-lymphopoiesis by interleukin 7 induces bone loss in mice with intact ovarian function: similarity to estrogen deficiency,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 17, pp. 9360–9365, 1997. View at Publisher · View at Google Scholar · View at Scopus
  239. T. Sato, T. Shibata, K. Ikeda, and K. Watanabe, “Generation of bone-resorbing osteoclasts from B220+ cells: its role in accelerated osteoclastogenesis due to estrogen deficiency,” Journal of Bone and Mineral Research, vol. 16, no. 12, pp. 2215–2221, 2001. View at Scopus
  240. G. Toraldo, C. Roggia, W. P. Qian, R. Pacific, and M. N. Weitzmann, “IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor κB ligand and tumor necrosis factor α from T cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 1, pp. 125–130, 2003. View at Publisher · View at Google Scholar · View at Scopus
  241. S. K. Lee, J. F. Kalinowski, S. L. Jastrzebski, L. Puddington, and J. A. Lorenzo, “Interleukin-7 is a direct inhibitor of in vitro osteoclastogenesis,” Endocrinology, vol. 144, no. 8, pp. 3524–3531, 2003. View at Publisher · View at Google Scholar · View at Scopus
  242. G. Eghbali-Fatourechi, S. Khosla, A. Sanyal, W. J. Boyle, D. L. Lacey, and B. L. Riggs, “Role of RANK ligand in mediating increased bone resorption in early postmenopausal women,” Journal of Clinical Investigation, vol. 111, no. 8, pp. 1221–1230, 2003. View at Publisher · View at Google Scholar · View at Scopus
  243. Y. Li, A. Li, X. Yang, and M. N. Weitzmann, “Ovariectomy-induced bone loss occurs independently of B cells,” Journal of Cellular Biochemistry, vol. 100, no. 6, pp. 1370–1375, 2007. View at Publisher · View at Google Scholar · View at Scopus
  244. T. J. Fry and C. L. Mackall, “Interleukin-7: master regulator of peripheral T-cell homeostasis?” Trends in Immunology, vol. 22, no. 10, pp. 564–571, 2001. View at Publisher · View at Google Scholar · View at Scopus
  245. M. Robbie-Ryan, R. Pacifici, and M. N. Weitzmann, “IL-7 drives T cell-mediated bone loss following ovariectomy,” Annals of the New York Academy of Sciences, vol. 1068, no. 1, pp. 348–351, 2006. View at Publisher · View at Google Scholar · View at Scopus
  246. M. Utsuyama and K. Hirokawa, “Hypertrophy of the thymus and restoration of immune functions in mice and rats by gonadectomy,” Mechanisms of Ageing and Development, vol. 47, no. 3, pp. 175–185, 1989. View at Scopus
  247. J. Pido-Lopez, N. Imami, and R. Aspinall, “Both age and gender affect thymic output: more recent thymic migrants in females than males as they age,” Clinical and Experimental Immunology, vol. 125, no. 3, pp. 409–413, 2001. View at Publisher · View at Google Scholar · View at Scopus
  248. M. K. Lindberg, J. Svensson, K. Venken et al., “Liver-derived IGF-I is permissive for ovariectomy-induced trabecular bone loss,” Bone, vol. 38, no. 1, pp. 85–92, 2006. View at Publisher · View at Google Scholar · View at Scopus
  249. S. K. Lee, J. F. Kalinowski, C. Jacquin, D. J. Adams, G. Gronowicz, and J. A. Lorenzo, “Interleukin-7 influences osteoclast function in vivo but is not a critical factor in ovariectomy-induced bone loss,” Journal of Bone and Mineral Research, vol. 21, no. 5, pp. 695–702, 2006. View at Publisher · View at Google Scholar · View at Scopus
  250. H. L. Aguila, S. H. Mun, J. Kalinowski, D. J. Adams, J. A. Lorenzo, and S. K. Lee, “Osteoblast-specific overexpression of human interleukin-7 rescues the bone mass phenotype of interleukin-7-deficient female mice,” Journal of Bone and Mineral Research, vol. 27, pp. 1030–1042, 2012.
  251. H. O. Valenzona, R. Pointer, R. Ceredig, and D. G. Osmond, “Prelymphomatous B cell hyperplasia in the bone marrow of interleukin-7 transgenic mice: precursor B cell dynamics, microenvironmental organization and osteolysis,” Experimental Hematology, vol. 24, no. 13, pp. 1521–1529, 1996. View at Scopus
  252. D. Salopek, D. Grčević, V. Katavić, N. Kovačić, I. K. Lukić, and A. Marušić, “Increased bone resorption and osteopenia are a part of the lymphoproliferative phenotype of mice with systemic over-expression of interleukin-7 gene driven by MHC class II promoter,” Immunology Letters, vol. 121, no. 2, pp. 134–139, 2008. View at Publisher · View at Google Scholar · View at Scopus
  253. A. Huston and G. D. Roodman, “Role of the microenvironment in multiple myeloma bone disease,” Future Oncology, vol. 2, no. 3, pp. 371–378, 2006. View at Publisher · View at Google Scholar · View at Scopus
  254. N. Giuliani, S. Colla, R. Sala et al., “Human myeloma cells stimulate the receptor activator of nuclear factor-κB ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease,” Blood, vol. 100, no. 13, pp. 4615–4621, 2002. View at Publisher · View at Google Scholar · View at Scopus
  255. N. Giuliani, S. Colla, F. Morandi et al., “Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation,” Blood, vol. 106, no. 7, pp. 2472–2483, 2005. View at Publisher · View at Google Scholar · View at Scopus
  256. S. D'Souza, D. del Prete, S. Jin et al., “Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease,” Blood, vol. 118, no. 26, pp. 6871–6880, 2011. View at Publisher · View at Google Scholar
  257. R. B. Kimble, S. Bain, and R. Pacifici, “The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice,” Journal of Bone and Mineral Research, vol. 12, no. 6, pp. 935–941, 1997. View at Publisher · View at Google Scholar · View at Scopus
  258. A. M. Tyagi, K. Srivastava, K. Sharan, D. Yadav, R. Maurya, and D. Singh, “Daidzein prevents the increase in CD4+CD28null T cells and B lymphopoesis in ovariectomized mice: a key mechanism for anti-osteoclastogenic effect,” PLoS ONE, vol. 6, no. 6, Article ID e21216, 2011. View at Publisher · View at Google Scholar · View at Scopus
  259. F. Gori, L. C. Hofbauer, C. R. Dunstan, T. C. Spelsberg, S. Khosla, and B. Lawrence Riggs, “The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated,” Endocrinology, vol. 141, no. 12, pp. 4768–4776, 2000. View at Publisher · View at Google Scholar · View at Scopus
  260. B. J. Kim, S. J. Bae, S. Y. Lee et al., “TNF-α mediates the stimulation of sclerostin expression in an estrogen-deficient condition,” Biochemical and Biophysical Research Communications, vol. 424, no. 1, pp. 170–175, 2012. View at Publisher · View at Google Scholar
  261. M. H. Sayegh, “Finally, CTLA4Ig graduates to the clinic,” Journal of Clinical Investigation, vol. 103, no. 9, pp. 1223–1225, 1999. View at Scopus
  262. A. Muhlethaler-Mottet, W. D. Berardino, L. A. Otten, and B. Mach, “Activation of the MHC class II transactivator CIITA by interferon-γ requires cooperative interaction between Stat1 and USF-1,” Immunity, vol. 8, no. 2, pp. 157–166, 1998. View at Publisher · View at Google Scholar · View at Scopus
  263. B. Ernst, D. S. Lee, J. M. Chang, J. Sprent, and C. D. Surh, “The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery,” Immunity, vol. 11, no. 2, pp. 173–181, 1999. View at Publisher · View at Google Scholar · View at Scopus
  264. C. Tanchot, F. A. Lemonnier, B. Pérarnau, A. A. Freitas, and B. Rocha, “Differential requirements for survival and proliferation of CD8 naive or memory T cells,” Science, vol. 276, no. 5321, pp. 2057–2062, 1997. View at Publisher · View at Google Scholar · View at Scopus
  265. C. D. Surh and J. Sprent, “Homeostasis of naive and memory T cells,” Immunity, vol. 29, no. 6, pp. 848–862, 2008. View at Publisher · View at Google Scholar · View at Scopus
  266. H. Takayanagi, K. Ogasawara, S. Hida et al., “T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ,” Nature, vol. 408, no. 6812, pp. 600–605, 2000. View at Publisher · View at Google Scholar · View at Scopus
  267. M. Pang, A. F. Martinez, J. Jacobs, W. Balkan, and B. R. Troen, “RANK ligand and interferon gamma differentially regulate cathepsin gene expression in pre-osteoclastic cells,” Biochemical and Biophysical Research Communications, vol. 328, no. 3, pp. 756–763, 2005. View at Publisher · View at Google Scholar · View at Scopus
  268. G. N. Mann, T. W. Jacobs, F. J. Buchinsky et al., “Interferon-γ causes loss of bone volume in vivo and fails to ameliorate cyclosporin A-induced osteopenia,” Endocrinology, vol. 135, no. 3, pp. 1077–1083, 1994. View at Publisher · View at Google Scholar · View at Scopus
  269. G. Duque, D. C. Huang, N. Dion et al., “Interferon-γ plays a role in bone formation in vivo and rescues osteoporosis in ovariectomized mice,” Journal of Bone and Mineral Research, vol. 26, no. 7, pp. 1472–1483, 2011. View at Publisher · View at Google Scholar · View at Scopus
  270. R. M. Rodriguiz, L. L. Key, and W. L. Ries, “Combination macrophage-colony stimulating factor and interferon-γ administration ameliorates the osteopetrotic condition in microphthalmic (mi/mi) mice,” Pediatric Research, vol. 33, no. 4, pp. 384–389, 1993. View at Scopus
  271. L. L. Key, R. M. Rodriguiz, S. M. Willi et al., “Long-term treatment of osteopetrosis with recombinant human interferon gamma,” The New England Journal of Medicine, vol. 332, no. 24, pp. 1594–1599, 1995. View at Publisher · View at Google Scholar · View at Scopus
  272. P. R. Madyastha, S. U. Yang, W. L. Ries, and L. L. Key Jr., “IFN-γ enhances osteoclast generation cultures of peripheral blood from osteopetrotic patients and normalizes superoxide production,” Journal of Interferon and Cytokine Research, vol. 20, no. 7, pp. 645–652, 2000. View at Publisher · View at Google Scholar · View at Scopus
  273. W. Huang, R. J. O'Keefe, and E. M. Schwarz, “Exposure to receptor-activator of NFκB ligand renders pre-osteoclasts resistant to IFN-γ by inducing terminal differentiation,” Arthritis Research & Therapy, vol. 5, no. 1, pp. R49–59, 2003. View at Scopus
  274. T. Yamaza, Y. Miura, Y. Bi et al., “Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents,” PLoS ONE, vol. 3, no. 7, Article ID e2615, 2008. View at Publisher · View at Google Scholar · View at Scopus
  275. S. K. Lee, Y. Kadono, F. Okada et al., “T lymphocyte-deficient mice lose trabecular bone mass with ovariectomy,” Journal of Bone and Mineral Research, vol. 21, no. 11, pp. 1704–1712, 2006. View at Publisher · View at Google Scholar · View at Scopus
  276. W. A. Goodman, K. D. Cooper, and T. S. McCormick, “Regulation generation: the suppressive functions of human regulatory T cells,” Critical Reviews in Immunology, vol. 32, no. 1, pp. 65–79, 2012.
  277. Y. G. Kim, C. K. Lee, S. S. Nah, S. H. Mun, B. Yoo, and H. B. Moon, “Human CD4+CD25+ regulatory T cells inhibit the differentiation of osteoclasts from peripheral blood mononuclear cells,” Biochemical and Biophysical Research Communications, vol. 357, no. 4, pp. 1046–1052, 2007. View at Publisher · View at Google Scholar · View at Scopus
  278. C. Y. Luo, L. Wang, C. Sun, and D. J. Li, “Estrogen enhances the functions of CD4+CD25+Foxp3+ regulatory T cells that suppress osteoclast differentiation and bone resorption in vitro,” Cellular and Molecular Immunology, vol. 8, no. 1, pp. 50–58, 2011. View at Publisher · View at Google Scholar · View at Scopus
  279. K. Wing, T. Yamaguchi, and S. Sakaguchi, “Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation,” Trends in Immunology, vol. 32, pp. 428–433, 2011.
  280. M. M. Zaiss, R. Axmann, J. Zwerina et al., “Treg cells suppress osteoclast formation: a new link between the immune system and bone,” Arthritis and Rheumatism, vol. 56, no. 12, pp. 4104–4112, 2007. View at Publisher · View at Google Scholar · View at Scopus
  281. R. Axmann, S. Herman, M. Zaiss et al., “CTLA-4 directly inhibits osteoclast formation,” Annals of the Rheumatic Diseases, vol. 67, no. 11, pp. 1603–1609, 2008. View at Publisher · View at Google Scholar · View at Scopus
  282. J. Goswami, N. Hernández-Santos, L. A. Zuniga, and S. L. Gaffen, “A bone-protective role for IL-17 receptor signaling in ovariectomy-induced bone loss,” European Journal of Immunology, vol. 39, no. 10, pp. 2831–2839, 2009. View at Publisher · View at Google Scholar · View at Scopus
  283. A. M. Tyagi, K. Srivastava, M. N. Mansoori, R. Trivedi, N. Chattopadhyay, and D. Singh, “Estrogen deficiency induces the differentiation of IL-17 secreting Th17 cells: a new candidate in the pathogenesis of osteoporosis,” PLoS ONE, vol. 7, Article ID e44552, 2012.
  284. S. C. Manolagas, “From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis,” Endocrine Reviews, vol. 31, no. 3, pp. 266–300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  285. S. C. Manolagas and M. Almeida, “Gone with the Wnts: β-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism,” Molecular Endocrinology, vol. 21, no. 11, pp. 2605–2614, 2007. View at Publisher · View at Google Scholar · View at Scopus
  286. J. M. Lean, J. T. Davies, K. Fuller et al., “A crucial role for thiol antioxidants in estrogen-deficiency bone loss,” Journal of Clinical Investigation, vol. 112, no. 6, pp. 915–923, 2003. View at Publisher · View at Google Scholar · View at Scopus
  287. J. M. Lean, C. J. Jagger, B. Kirstein, K. Fuller, and T. J. Chambers, “Hydrogen peroxide is essential for estrogen-deficiency bone loss and osteoclast formation,” Endocrinology, vol. 146, no. 2, pp. 728–735, 2005. View at Publisher · View at Google Scholar · View at Scopus
  288. S. Kantengwa, L. Jornot, C. Devenoges, and L. P. Nicod, “Superoxide anions induce the maturation of human dendritic cells,” American Journal of Respiratory and Critical Care Medicine, vol. 167, no. 3, pp. 431–437, 2003. View at Publisher · View at Google Scholar · View at Scopus
  289. E. Bjorgo and K. Tasken, “Novel mechanism of signaling by CD28,” Immunology Letters, vol. 129, pp. 1–6, 2010.
  290. P. D'Amelio, A. Grimaldi, S. Di Bella et al., “Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis,” Bone, vol. 43, no. 1, pp. 92–100, 2008. View at Publisher · View at Google Scholar · View at Scopus
  291. J. S. Lindberg and S. M. Moe, “Nephrology-specific issues in women's health osteoporosis in end-stage renal disease,” Seminars in Nephrology, vol. 19, no. 2, pp. 115–122, 1999. View at Scopus
  292. H. Tawfeek, B. Bedi, J. Y. Li et al., “Disruption of PTH receptor 1 in t cells protects against PTH-induced bone loss,” PLoS ONE, vol. 5, no. 8, Article ID e12290, 2010. View at Publisher · View at Google Scholar · View at Scopus
  293. S. Nishida, A. Yamaguchi, T. Tanizawa et al., “Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow,” Bone, vol. 15, no. 6, pp. 717–723, 1994. View at Publisher · View at Google Scholar · View at Scopus
  294. A. B. Hodsman, D. C. Bauer, D. W. Dempster et al., “Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use,” Endocrine Reviews, vol. 26, no. 5, pp. 688–703, 2005. View at Publisher · View at Google Scholar · View at Scopus
  295. E. C. Weir, C. W. G. M. Lowik, I. Paliwal, and K. L. Insogna, “Colony stimulating factor-1 plays a role in osteoclast formation and function in bone resorption induced by parathyroid hormone and parathyroid hormone-related protein,” Journal of Bone and Mineral Research, vol. 11, no. 10, pp. 1474–1481, 1996. View at Scopus
  296. Y. L. Ma, R. L. Cain, D. L. Halladay et al., “Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation,” Endocrinology, vol. 142, no. 9, pp. 4047–4054, 2001. View at Publisher · View at Google Scholar · View at Scopus
  297. B. G. Hory, M. C. Roussanne, S. Rostand, A. Bourdeau, T. B. Drüeke, and J. Gogusev, “Absence of response to human parathyroid hormone in athymic mice grafted with human parathyroid adenoma, hyperplasia or parathyroid cells maintained in culture,” Journal of Endocrinological Investigation, vol. 23, no. 5, pp. 273–279, 2000. View at Scopus
  298. T. J. Rosol, C. C. Capen, and R. L. Horst, “Effects of infusion of human parathyroid hormone-related protein-(1-40) in nude mice: histomorphometric and biochemical investigations,” Journal of Bone and Mineral Research, vol. 3, no. 6, pp. 699–706, 1988. View at Scopus
  299. H. E. Alten and P. Groscurth, “The postnatal development of the ovary in the “nude” mouse,” Anatomy and Embryology, vol. 148, no. 1, pp. 35–46, 1975. View at Scopus
  300. H. Nagasawa and R. Yanai, “Mammary growth and function and pituitary prolactin secretion in female nude mice,” Acta Endocrinologica, vol. 86, no. 4, pp. 794–802, 1977. View at Scopus
  301. Y. Gao, X. Wu, M. Terauchi et al., “T cells potentiate PTH-induced cortical bone loss through CD40L signaling,” Cell Metabolism, vol. 8, no. 2, pp. 132–145, 2008. View at Publisher · View at Google Scholar · View at Scopus
  302. B. Bedi, J. Y. Li, F. Grassi, H. Tawfeek, M. N. Weitzmann, and R. Pacifici, “Inhibition of antigen presentation and T cell costimulation blocks PTH-induced bone loss,” Annals of the New York Academy of Sciences, vol. 1192, pp. 215–221, 2010. View at Publisher · View at Google Scholar · View at Scopus
  303. R. M. Neer, C. D. Arnaud, J. R. Zanchetta et al., “Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis,” The New England Journal of Medicine, vol. 344, no. 19, pp. 1434–1441, 2001. View at Publisher · View at Google Scholar · View at Scopus
  304. I. U. Schmidt, H. Dobnig, and R. T. Turner, “Intermittent parathyroid hormone treatment increases osteoblast number, steady state messenger ribonucleic acid levels for osteocalcin, and bone formation in tibial metaphysis of hypophysectomized female rats,” Endocrinology, vol. 136, no. 11, pp. 5127–5134, 1995. View at Scopus
  305. H. Dobnig and R. T. Turner, “Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells,” Endocrinology, vol. 136, no. 8, pp. 3632–3638, 1995. View at Scopus
  306. G. J. Pettway, J. A. Meganck, A. J. Koh, E. T. Keller, S. A. Goldstein, and L. K. McCauley, “Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation,” Bone, vol. 42, no. 4, pp. 806–818, 2008. View at Publisher · View at Google Scholar · View at Scopus
  307. R. L. Jilka, “Molecular and cellular mechanisms of the anabolic effect of intermittent PTH,” Bone, vol. 40, no. 6, pp. 1434–1446, 2007. View at Publisher · View at Google Scholar · View at Scopus
  308. R. L. Jilka, R. S. Weinstein, T. Bellido, P. Roberson, A. M. Parfitt, and S. C. Manolagas, “Increased bone formation byprevention of osteoblast apoptosis with parathyroid hormone,” Journal of Clinical Investigation, vol. 104, no. 4, pp. 439–446, 1999. View at Scopus
  309. T. Bellido, A. A. Ali, L. I. Plotkin et al., “Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts: a putative explanation for why intermittent administration is needed for bone anabolism,” Journal of Biological Chemistry, vol. 278, no. 50, pp. 50259–50272, 2003. View at Publisher · View at Google Scholar · View at Scopus
  310. P. V. N. Bodine and B. S. Komm, “Wnt signaling and osteoblastogenesis,” Reviews in Endocrine & Metabolic Disorders, vol. 7, no. 1-2, pp. 33–39, 2006. View at Publisher · View at Google Scholar · View at Scopus
  311. T. Bellido, A. A. Ali, I. Gubrij et al., “Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis,” Endocrinology, vol. 146, no. 11, pp. 4577–4583, 2005. View at Publisher · View at Google Scholar · View at Scopus
  312. G. Hardiman, S. Albright, J. I. Tsunoda, T. McClanahan, and F. Lee, “The mouse Wnt-10B gene isolated from helper T cells is widely expressed and a possible oncogene in BR6 mouse mammary tumorigenesis,” Gene, vol. 172, no. 2, pp. 199–205, 1996. View at Publisher · View at Google Scholar · View at Scopus
  313. Y. Ouji, M. Yoshikawa, A. Shiroi, and S. Ishizaka, “Wnt-10b secreted from lymphocytes promotes differentiation of skin epithelial cells,” Biochemical and Biophysical Research Communications, vol. 342, no. 4, pp. 1063–1069, 2006. View at Publisher · View at Google Scholar · View at Scopus
  314. M. Terauchi, J. Y. Li, B. Bedi et al., “T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling,” Cell Metabolism, vol. 10, no. 3, pp. 229–240, 2009. View at Publisher · View at Google Scholar · View at Scopus
  315. B. Bedi, J. Y. Li, H. Tawfeek et al., “Silencing of parathyroid hormone (PTH) receptor 1 in T cells blunts the bone anabolic activity of PTH,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 12, pp. E725–E733, 2012. View at Publisher · View at Google Scholar
  316. J. J. Goronzy and C. M. Weyand, “T-cell senescence and contraction of T-cell repertoire diversity—catalysts of autoimmunity and chronic inflammation,” Arthritis Research and Therapy, vol. 5, no. 5, pp. 225–234, 2003. View at Scopus
  317. A. N. Vallejo, M. Schirmer, C. M. Weyand, and J. J. Goronzy, “Clonality and longevity of CD4+CD28(null) T cells are associated with defects in apoptotic pathways,” Journal of Immunology, vol. 165, no. 11, pp. 6301–6307, 2000. View at Scopus
  318. M. H. Weisman, “What are the risks of biologic therapy in rheumatoid arthritis? An update on safety,” Journal of Rheumatology, vol. 29, no. 65, pp. 33–38, 2002. View at Scopus